Short answer
Cardiff Oncology, Inc. (CRDF) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.03 (Amendments to Articles of Incorporation or Bylaws), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Chief Medical Officer Roger Sidhu departed October 22, 2026 through a mutually agreed transition.
Cardiff Oncology, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Chief Medical Officer Roger Sidhu departed October 22, 2026 through a mutually agreed transition
- Leila Alland appointed interim Chief Medical Officer effective October 23, 2026
- Interim appointment runs through April 22, 2027 unless services conclude earlier
- Consulting fee $35,000 monthly, with up to 50% professional time dedicated to Cardiff
- Leadership change places clinical development oversight with an oncology executive experienced across multiple biotech companies
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Authorized common shares increased to 300,000,000, expanding potential equity issuance capacity
- Effective October 22, 2026 upon Delaware filing
- Greater authorization supports financing flexibility but creates potential shareholder dilution risk
Item 7.01 · Regulation FD Disclosure
- Dr. Sidhu resigned as Chief Medical Officer, creating a senior clinical leadership transition
- Dr. Alland appointed interim Chief Medical Officer, providing temporary oversight of clinical development
- Leadership change potentially relevant to CRDF’s trial execution, regulatory strategy and investor confidence
Item EX-99.1 · Exhibit EX-99.1
- Leila Alland, MD appointed interim Chief Medical Officer, replacing Roger Sidhu
- Leadership change arrives before planned Phase 3 launch in first quarter 2027
- Phase 2 colorectal cancer trial ongoing, with median PFS not reached in proposed Phase 3 regimen
- Remaining trial patients have received treatment for more than 18 months, supporting continued clinical focus on durability
- Appointment adds oncology development expertise but creates interim leadership uncertainty ahead of registration-enabling execution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Cardiff Oncology, Inc. 8-K filings
Get the next CRDF 8-K as it lands
Follow CRDF for push alerts, or ask the research agent what this filing means.